Plain-English translation of NCT06735560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called 89Zr-TLX250, which uses a special tracer (a harmless radioactive marker) to help doctors see certain cancers more clearly. The scan targets a protein called CAIX that appears on three types of cancer: hepatocellular carcinoma (liver cancer), cholangiocarcinoma (bile duct cancer), and gastro-entero-pancreatic neuroendocrine tumors. Researchers want to know if this medication can help doctors find these cancers and plan better treatment.
Current imaging methods sometimes miss these cancers or don't show them clearly enough. This new treatment offers a way to specifically target and visualize these tumors, which could help doctors catch them earlier and choose the right treatments more accurately.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the experimental imaging medication and then undergo a PET-CT scan. The scan is painless and allows doctors to see where the cancer is in your body using the special tracer. You may need to wait a short time after injection for the tracer to work, and the scan itself typically takes 30–60 minutes. Your participation will be brief, and the study team will use the images to evaluate how well this new imaging approach detects your cancer.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France